Af­ter No­var­tis left, Boehringer bets up to $500M on the field of pre­scrip­tion smart­phone apps

Boehringer In­gel­heim wants in on dig­i­tal ther­a­peu­tics.

The Ger­man phar­ma signed an up to $500 mil­lion col­lab­o­ra­tion with Click Ther­a­peu­tics, one of a hand­ful of ma­jor com­pa­nies de­vel­op­ing pre­scrip­tion com­put­er and smart­phone ap­pli­ca­tions for var­i­ous neu­ro­log­i­cal or men­tal dis­or­ders. They join a small list of phar­mas that have de­cid­ed to test the wa­ters in the emerg­ing field.

Un­der the deal, Boehringer and Click will co-de­vel­op a dig­i­tal ther­a­peu­tic for schiz­o­phre­nia, known as CT-155. It’s a com­ple­men­tary ef­fort to Boehringer’s more tra­di­tion­al schiz­o­phre­nia work. The com­pa­ny has con­cen­trat­ed their neu­ro­science ef­forts there since 2018, when a Phase II fail­ure blew up their late-stage Alzheimer’s ef­forts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER